Inhaleen (iota-carrageenan) / Marinomed Biotech - LARVOL DELTA

Lubricating Effectiveness of Carragelose Eye Drops in Patients Affected by Mild to Moderate Dry Eye (clinicaltrials.gov) - P=N/A | N=30 | Completed | Sponsor: Marinomed Biotech AG | Recruiting ➔ Completed | Trial completion date: Dec 2024 ➔ Jul 2024

Trial completion • Trial completion date • Dry Eye Disease • Ophthalmology

Decongestant Effect of "Coldamaris Akut", a Carrageenan- and Sorbitol-Containing Nasal Spray in Seasonal Allergic Rhinitis. (PubMed, Int J Gen Med) - P=N/A | "We propose CS as a safe and effective adjuvant to baseline pharmacological treatments. NCT04532762."

Clinical • Journal • Allergic Rhinitis • Immunology • Inflammation

Lubricating Effectiveness of Carragelose Eye Drops in Patients Affected by Mild to Moderate Dry Eye (clinicaltrials.gov) - P=N/A | N=30 | Recruiting | Sponsor: Marinomed Biotech AG

New trial • Dry Eye Disease • Ophthalmology

"#2022 was a busy and successful year for #Marinomed. Read here a quick summary of Q1 2022. #virology #immunology #solv4u #carragelose #marinosolv #oceanofideas #investor #genderdiversitychampion #bioeurope #conferences #businessdevelopment ©Photos: GEWINN, Marinomed" (@Marinomed_AG)

Immunology

A study protocol for a double-blind randomised placebo-controlled trial evaluating the efficacy of carrageenan nasal and throat spray for COVID-19 prophylaxis-ICE-COVID. (PubMed, Trials) - P=N/A | "This is a single-centre, phase III, double-blind, randomised placebo-controlled clinical trial to assess whether carrageenan nasal and throat spray reduces the risk of development and severity of COVID-19. If proven effective, the self-administered prophylactic spray would have wider utility for key workers and the general population."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Efficacy and Safety Evaluation of Inhaleen Inhalation in Hospitalized COVID-19 Patients (clinicaltrials.gov) - P=N/A | N=14 | Completed | Sponsor: Marinomed Biotech AG | Recruiting ➔ Completed | N=228 ➔ 14 | Trial completion date: Oct 2021 ➔ Jul 2022 | Trial primary completion date: Jun 2021 ➔ Jul 2022

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Prophylactic Treatment With Carragelose Nasal Spary to Prevent SARS-CoV-2, COVID-19, Infections in Health Care Workers (clinicaltrials.gov) - P=N/A | N=300 | Completed | Sponsor: Marinomed Biotech AG | Recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

"#IvermectinWarriors #ivermectinworks 0.3 mg/kg q4d N100 respirator indoors Carragelose tid Mint Listerine gargle 30s qid 25(OH)D 70-100 ng/ml cc: @US_FDA @NIH @CDCgov" (@FOHMaster)

"C'est la meme chose: carragelose" (@dronico)

"Carragelose is sold under this brands in different countries https://t.co/qq93MqWc1S" (@dronico)

"Pardon : carragelose. Erreur de typographie" (@Charles18589678)

Efficacy and Safety Evaluation of Inhaleen Inhalation in Hospitalized COVID-19 Patients (clinicaltrials.gov) - P=N/A; N=228; Recruiting; Sponsor: Marinomed Biotech AG

Clinical • New trial • Infectious Disease • Novel Coronavirus Disease

Prophylactic Treatment With Carragelose Nasal Spary to Prevent SARS-CoV-2, COVID-19, Infections in Health Care Workers (clinicaltrials.gov) - P=N/A; N=300; Recruiting; Sponsor: Marinomed Biotech AG; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Prophylactic Treatment With Carragelose Nasal Spary to Prevent SARS-CoV-2, COVID-19, Infections in Health Care Workers (clinicaltrials.gov) - P=N/A; N=300; Not yet recruiting; Sponsor: Marinomed Biotech AG

Clinical • New trial • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Marinomed plans a clinical trial with Carragelose nasal spray as COVID-19 prophylaxis (News-Medical) - "Marinomed Biotech AG...is pleased to announce today that the Swansea University Medical School plans a clinical trial with Iota-/kappa-carrageenan nasal spray as a COVID-19 Prophylaxis for Healthcare Professionals (ICE-COVID). The investigator-initiated trial at Swansea will be recruiting 480 healthcare professionals managing COVID-19 patients during the pandemic....The design of the double-blind trial is finalized and planned to start shortly."

New trial • Infectious Disease • Novel Coronavirus Disease